GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Milestone Pharmaceuticals Inc (NAS:MIST) » Definitions » GF Value

MIST (Milestone Pharmaceuticals) GF Value : $0.00 (As of Apr. 05, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Milestone Pharmaceuticals GF Value?

As of today (2025-04-05), Milestone Pharmaceuticals's share price is $0.6976. Milestone Pharmaceuticals's GF Value is $0.00. Therefore, Milestone Pharmaceuticals's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Milestone Pharmaceuticals is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

  1. We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
  2. We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
  3. Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.


Milestone Pharmaceuticals  (NAS:MIST) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Milestone Pharmaceuticals's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=0.6976/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Milestone Pharmaceuticals GF Value Related Terms

Thank you for viewing the detailed overview of Milestone Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Milestone Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Executives
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
David Bharucha officer: Chief Medical Officer C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Debra K. Liebert director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6
Richard C Pasternak director C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6
Michael John Tomsicek director 28 OVERLOOK DRIVE, BEDFORD MA 01730
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jeffrey Edward Nelson officer: Chief Operating Officer C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Fonds De Solidarite Des Travailleurs Du Quebec 10 percent owner 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Novo Holdings A/s 10 percent owner, other: SEE REMARKS TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Amit Hasija officer: CFO & EVP of Corp. Development C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6
Lorenz Muller officer: Chief Commercial Officer C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6